NDT Advance Access originally published online on May 25, 2006
Nephrology Dialysis Transplantation 2006 21(8):2060-2063; doi:10.1093/ndt/gfl219
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nephrotoxicity of ciclosporin A: short-term gain, long-term pain?
Centre for Transplant and Renal Research, Millenium Institute, Westmead Hospital, University of Sydney, Australia
Correspondence and offprint requests to: Jeremy R. Chapman, Centre for Transplant and Renal Research, Millenium Institute, University of Sydney, Westmead Hospital, Westmead NSW 2145, Australia. Email: jeremy_chapman{at}wsahs.nsw.gov.au
Keywords: chronic allograft nephropathy; ciclosporin; nephrotoxicity
 |
Historical perspective |
|---|
 Top Historical perspective Acute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
Ciclosporin (CsA) was first dosed in pilot renal transplant recipients at 25 mg/kg/day, based upon large animal experimental data [1], but was rapidly found to be nephrotoxic and the dose reduced to 10 mg/kg/day. Monotherapy at this dose was, however, found to provide inadequate immunosuppression [2] and a starting dose of 17.5 mg/kg/day was thus used in the early phase II/III of clinical studies [3,4]. This early experience changed the clinical practice of transplantation, since acute rejection became a more subtle clinical syndrome and a differential diagnosis of acute nephrotoxicity had to be considered for renal dysfunction. The therapeutic window of CsA, when used alone, proved too narrow and thus, triple therapy, including azathioprine and low-dose prednisolone was born in the late 1980s [5]. The histological picture of acute CsA nephrotoxicity was defined both in transplanted and native kidneys, with the widely agreed hallmarks being striped or diffuse interstitial fibrosis, nodular arteriolar hyalinosis and tubular calcification [6].
|
Acute nephrotoxicity |
|---|
|
TopHistorical perspectiveAcute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
The functional impact of CsA nephrotoxicity appeared in the early formal randomized clinical trials [3,4,7] with impaired tubular function, higher serum urate levels and altered potassium handling. Blood pressure was increased and glomerular filtration rate (GFR) was reduced, but rapid recovery to control levels was observed after cessation of the drug. Synergisitic toxicity with non-steroidal anti-inflammatory agents hinted at the vascular nature of the functional insult caused by CsA. Histological confirmation of CsA nephrotoxicity was seldom forthcoming in patients with acute rises in serum creatinine and clinicians learnt to rely for diagnosis, on an absence of the histological features of rejection together with a response to dose reduction. The reassurance that CsA nephrotoxicity was reversible—at least after 3 months of treatment—was encouraging, but the words of warning in those early papers with respect to uncertainty over reversibility in the longer term, went unheeded [7]. Short-term graft survival rates continued to improve throughout the 1990s and little attention was paid to the longer-term outcomes.
|
Chronic nephrotoxicity |
|---|
|
TopHistorical perspectiveAcute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
The concern that chronic calcineurin inhibitor (CNI) nephrotoxicity was a major long-term problem should have been widely understood in the mid-1990s through the longer-term follow-up of trials of CsA treated patients [8,9]. Shorter-term pathology studies, such as that from a randomized trial of CsA and tacrolimus, also showed that 60–70% of patients in both groups had chronic histological damage at only 2 years after transplantation [10]. Definitive evidence that CsA nephrotoxicity impacted graft survival has been elusive, but two analyses of Australian data—both registry and long-term follow-up of an early randomised controlled study—clearly showed worse long-term outcomes in those maintained on CsA compared with those maintained without CsA [11,12].
The view developed during the late 1990s that ‘chronic rejection’ was an inappropriate term and that ‘chronic allograft nephropathy’ (CAN) was better. It became evident that multiple antecedent insults contributed to this histological picture, including ischaemia, acute and chronic allograft rejection and perhaps also CNI nephrotoxicity [13,14]. The true impact of CsA nephrotoxicity has thus been disguised over the past 15 years by a lack of data, lack of enquiry, lack of alternatives and therapeutic nihilism.
The histological studies that we commenced at Westmead in 1987 and reported in 2003 and 2004 [15–19] when added to other voices [9,20] threw an urgency into the debate over how to treat and avoid CAN [21]. It is now clear that chronic CNI nephrotoxicity causes long-term histological damage which is grossly underestimated by the renal functional change and which becomes largely irreversible by the time an elevated serum creatinine has alarmed either the clinician or the patient.
|
Histological predictors |
|---|
|
TopHistorical perspectiveAcute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
The early histological hallmarks of acute CNI nephrotoxicity [22] are usually present between 3 and 12 months after transplantation, and include transient de novo nodular arteriolar hyalinosis, striped cortical fibrosis, tubular microcalcification, juxta glomerular hyperplasia and isometric tubular vacuolization. The data correlating these histological changes with measures of CsA exposure have, however, been limited [17]. This picture is associated with the preceding episodes of acute CNI-induced renal dysfunction and is exacerbated by delayed graft function.
The chronic phase of CNI nephrotoxicity was seen in the Westmead histology study at a mean of 3 years after transplantation, increasing with time, until striped cortical fibrosis, severe circumferential and nodular arteriolar hyalinosis, and tubular calcification were present in the vast majority of patients who had used CsA for 10 years, 50% of whom had Banff criteria for grade III CAN [15]. While this knowledge is sufficient to destroy the hypothesis that striped fibrosis and arteriolar hyalinosis are simply the products of acute CsA overdosing, perhaps the most interesting correlates in this histology series are the impacts that these features have on subsequent glomerular sclerosis [19].
Interstitial fibrosis is followed by the development of glomerular sclerosis—and there was, in our data, several years’ delay between the observation of interstitial fibrosis and the development of significant glomerular sclerosis. Two-thirds of interstitial fibrosis occurred in the first year, as the combined result of ischaemia, CsA nephrotoxicity, severe acute rejection and other toxic agents. Subsequent fibrosis came largely from an insidious development of CsA nephrotoxicity in the form of striped fibrosis associated with arteriolar hyalinosis, or more rarely from persistent subclinical rejection. The amount of interstitial fibrosis, scored using the Banff schema for ci, seen at 1 year correlated significantly with the degree of early glomerular sclerosis in that same kidney later between 1 and 4 years [18], perhaps through the formation of atubular glomeruli. The second factor that correlated with glomerular sclerosis was the degree of arteriolar hyalinosis, further supporting the linkage between microvascular injury and ischaemic glomerulosclerosis [17]. If preventative action is to improve graft outcomes, then the histological data would suggest that we must put research effort into either preventing interstitial fibrosis or arteriolar hyalinosis, or de-linking the relationship between these events and glomerular sclerosis.
|
Exacerbating factors |
|---|
|
TopHistorical perspectiveAcute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
CsA dosing has been associated with the degree of histological change. The greater the dose, the more likely are the histological changes of both acute and chronic CNI toxicity. Acute arteriolar hyalinosis may resolve with dose reduction, though striped cortical fibrosis is an irreversible injury. In the Westmead study, a mean CsA dose above 5 mg/kg/day was associated with the development of permanent histological changes by 5 years after transplantation, though even those patients using lower doses mostly developed histological features of chronic CsA nephrotoxicity by 10 years [17].
In pivotal phase III studies of sirolimus and everolimus, both unwittingly demonstrated that the combination of this class of drugs with a CNI increased CNI nephrotoxocity [23,24]: the mechanism for which may be through a pharmacodynamic interaction which leads to intracellular accumulation of the CNI in tubular cells [25]. Interestingly, the histological impact of the withdrawal of a CNI was also demonstrated in the histology sub-study of the much-quoted trial of CsA withdrawal from a triple therapy regimen including CsA, sirolimus and corticosteroids [26]. This study showed an improvement in renal function and in the degree of tubular atrophy in the grafts in which CsA was withdrawn.
|
Strategies for avoiding chronic nephrotoxicity |
|---|
|
TopHistorical perspectiveAcute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
The simplest strategy for avoiding CNI nephrotoxicity is clearly to avoid using the class of drugs, but this approach has often failed because alternative drugs of comparable immunosuppressive efficacy have not been available. This simple conundrum has lead to continuing attempts to use short-term CNI, for perhaps 3 months, and then to eliminate the CNI in favour of less nephrotoxic alternatives (Table 1). Structured meta-analysis of CsA elimination both in favour of azathioprine in combination with steroids, [27] and sirolimus and steroids [28] has demonstrated improved graft function, no impact on short-term graft survival, but a small increase in immediate post-elimination/conversion acute rejection rates, in the order of 8–11%. It may be the small immediate risk of acute rejection that is preventing widespread clinical implementation of such strategies.
|
An alternative approach involves avoiding CNIs entirely through a combination of sirolimus with mycophenolate mofetil, prednisolone and either monoclonal antibody to the Il2 receptor [29] or Campath 1H [30]. This strategy may prove practical in the long term, but also has short-term consequences [29,30]. The most recently reported study of CNI-free therapy compared tacrolimus with sirolimus, both in combination with thymoglobulin, mycophenolate mofetil and corticosteroids in a predominantly low-risk living donor transplant population [31]. The excellent outcome in both groups (1 year: patient survival of 98 and 96%; graft survival 94 and 92%; and measured GFR 55 vs 55 ml/min/1.73 m2) underlines the difficulty of distinguishing long-term results from the short-term data. One year protocol biopsies showed similar degrees of interstitial fibrosis but more chronic vascular disease in the tacrolimus group, perhaps hinting at the potential for long-term differences.
In conclusion, long-term follow-up of clinical and histological data on patients either withdrawn from or never exposed to CNIs will be needed to demonstrate if the early pain is worth the long term gain.
Conflict of interest statement. JRC is an advisory Board and speaker panels for Novartis, Wyeth, Astellas and Roche.
|
References |
|---|
|
TopHistorical perspectiveAcute nephrotoxicityChronic nephrotoxicityHistological predictorsExacerbating factorsStrategies for avoiding chronic...References |
|---|
- Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978; 2: 1323–1327[Web of Science][Medline]
- Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033–1036[Web of Science][Medline]
- Morris PJ, Chapman JR, Allen RD, et al. Cyclosporin conversion versus conventional immunosuppression: long term follow up and histological evaluation. Lancet 1987; 2: 586–591
- Hall BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaver renal transplantation: long term cyclosporine, short term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1988; 318: 1499–1507[Abstract]
- Slapak M, Geoghegan T, Digard N, Ahmed K, Sharman VL, Crockett R. The use of low-dose cyclosporine A in combination with azathioprine and steroids in renal transplantation. Transplant Proc 1987; 19 [2 Suppl 2]: 41–45
- Mihatsch MI, Theil G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988; 20 [3 Suppl 3]: 759
- Chapman JR, Griffiths D, Harding N, Morris PJ. The reversibility of cyclosporin nephrotoxicity after three months treatment. Lancet 1985; 1: 128–130[CrossRef][Web of Science][Medline]
- European multicentre trial of cyclosporine in renal transplantation: ten year follow-up. Transplant Proc 1993; 25 1pt 1: 527
- Hollander AA, van Saase JL, Kootte AM, et al. Beneficial effects of conversion from cyclosporin to azathioprine after kidney transplantation. Lancet 1995; 345: 610–614[CrossRef][Web of Science][Medline]
- Solez K, Vincenti F, Filo RS. Histopathology findings from 2 year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 1998; 66: 1736–1740[CrossRef][Web of Science][Medline]
- Mathew TH, McDonald SP, Russ GR. Renal transplant outcome beyond five years. Effect of donor and recipient factors and immunosuppression. ANZDATA Registry Report 2001, 112–115. Australia and New Zealand Dialysis and Transplant Registry. Adelaide South Australia
- Gallagher MP, Hall B, Craig J, Berry G, Tiller DJ, Eris J. Australian Multicenter Trial of Cyclosporine Withdrawal Study Group and the ANZ Dialysis and Transplantation Registry. A randomized controlled trial of cyclosporine withdrawal in renal-transplant recipients: 15-year results. Transplantation 2004; 78: 1653–1660[CrossRef][Web of Science][Medline]
- Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1995; 55: 713–723
- Nankivell BJ, Fenton-Lee CA, Kuypers DRJ, et al. Effect of histological damage on long-term kidney transplant outcome. Transplantation 2001; 71: 515–523[CrossRef][Web of Science][Medline]
- Nankivell BJ, Borrows RJ, O’Connell PJ, Allen RDM, Chapman JR. The natural history of chronic allograft nephropathy. New Engl J Med 2003; 349: 2326–2333
[Abstract/Free Full Text] - Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Allen RDM, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242–249[Web of Science][Medline]
- Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Chapman JR, Allen RDM. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004; 78: 557–565[Web of Science][Medline]
- Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Chapman JR, Allen RDM. Delta analysis of posttransplantation tubulointerstitial damage. Transplantation 2004; 78: 434–441[CrossRef][Web of Science][Medline]
- Nankivell BJ, Borrows RJ, Fung CL-S, O’Connell PJ, Allen RDM, Chapman JR. Evolution and pathophysiology of renal-transplant glomerulosclerosis. Transplantation 2004; 78: 557–565[Web of Science][Medline]
- Myers BB, Newton L. Cyclosporine-induced chronic nephropathy: an obliterative microvascular renal injury. J Am Soc Nephrology 1991; 2 [Suppl 1]: S45–S52
- Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015–3026
[Abstract/Free Full Text] - Mihatsch MI, Ryfell B, Gudat F. The differential diagnosis between rejection and cyclosporine toxicity. Kidney Int 1995; 52: S63–S69
- Kahan BD, Camardo JS. Rapamycin: clinical results and future opportunities. Transplantation 2001; 72: 1181–1193[CrossRef][Web of Science][Medline]
- Vitko S, Margreiter R, Weimar W, et al. RAD B201 Study Group. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521–2530[CrossRef][Web of Science][Medline]
- Podder H, Stepkowski SM, Napoli KL, et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059–1071
[Abstract/Free Full Text] - Mota A, Arias M, Taskinen EI, et al. Rapamune Maintenance Regimen Trial. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953–961[CrossRef][Web of Science][Medline]
- Kasiske BL, Chakkera HA, Louis TA, Ma JZ. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910–1917
[Abstract/Free Full Text] - Mulay AV, Hussain N, Fergusson D, Knoll GA. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: a systematic review of randomized trials. Am J Transplant 2005; 5: 1748–1755[CrossRef][Web of Science][Medline]
- Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070–1076[CrossRef][Web of Science][Medline]
- Flechner SM, Friend PJ, Brockmann J, et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009–3014[CrossRef][Web of Science][Medline]
- Larson TS, Dean PG, Stegall MD, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514–522[CrossRef][Web of Science][Medline]
Accepted in revised form: 29. 3.06
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. D. Dudgeon, N. Zhang, O. O. Ositelu, H. Kim, and K. W. Cunningham Nonapoptotic Death of Saccharomyces cerevisiae Cells That Is Stimulated by Hsp90 and Inhibited by Calcineurin and Cmk2 in Response to Endoplasmic Reticulum Stresses Eukaryot. Cell, December 1, 2008; 7(12): 2037 - 2051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lee, W. Kim, D. H. Kim, S.-O. Moon, Y. J. Jung, A. S. Lee, K. P. Kang, K. Y. Jang, S. Y. Lee, M. J. Sung, et al. Protective effect of COMP-angiopoietin-1 on cyclosporine-induced renal injury in mice Nephrol. Dial. Transplant., September 1, 2008; 23(9): 2784 - 2794. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Seron, W. Arns, and J. R. Chapman Chronic allograft nephropathy--clinical guidance for early detection and early intervention strategies Nephrol. Dial. Transplant., August 1, 2008; 23(8): 2467 - 2473. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||